• Faculty Member Photo
  • Jane L. Burns, MD
    Professor of Pediatric Infectious Diseases
    Email: click here
    Phone: (206) 987-2073

Dr. Burns’ primary area of research for many years has been cystic fibrosis (CF) microbiology, including antibiotic resistance and bacterial pathogenesis. Her studies have used both in vitro and in vivo models of infection. Novel methods of in vitro susceptibility testing have been established, including testing drug activity against bacteria grown in biofilms and examining drug bioactivity in the presence of CF sputum. She has worked with both primary CF cells and immortalized cell lines in tissue culture to examine bacterial pathogenesis including attachment, invasion and apoptosis. In vivo experiments use a mouse model of chronic bacterial infections with Pseudomonas aeruginosa and Burkholderia cepacia complex. Recent work is examining the phenotypic and genotypic adaptations of both organisms to growth within the CF airway. Dr. Burns frequently collaborates with clinical and basic science CF researchers at Seattle Children’s Hospital and the University of Washington. In addition, she directs the Center for CF Microbiology at Seattle Children’s Hospital, which is a core laboratory for the CF Foundation Therapeutics Development Network.

University of Washington, B.S., Biology, 1974

Medical School
University of Washington, 1978

Children’s Hospital and Regional Medical Center/University of Washington, 1978-81
Chief Pediatric Resident, 1981-82

Children’s Hospital and Regional Medical Center/University of Washington, Pediatric Infectious Diseases, 1982-85

1. Gibson, R.L., Emerson, J., McNamara, S., Burns, J.L., Rosenfeld, M., et al.: Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167:841-849, 2003.

2. Saiman, L., Burns, J.L., Larone, D., Chen, Y., Garber, E., and Whittier, S.: Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 41:492-494, 2003.

3. Spencer, D.H., Kas, A., Smith, E.E., Raymond, C.K., Sims, E.H., Hastings, M., Burns, J.L., Kaul, R., and Olson, M.V.: Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol 185:1316-1325, 2003.

4. Tomich, M., Griffith, A., Herfst, C.A., Burns, J.L., and Mohr, C.D.: Attenuated virulence of a Burkholderia cepacia Type III secretion mutant in a murine model of infection. Infect Immun 71:1405-1415, 2003.

5. Aitken, M.L., Greene, K.E., Tonelli, M.R., Burns, J.L., Emerson, J.C., Goss, C.H., and Gibson, R.L.: Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis. Chest 123:792-799, 2003.

6. Smith, A.L., Fiel, S.B., Mayer-Hamblett, N., Ramsey, B., and Burns, J.L.: Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123:1495-1502, 2003.

7. Qin, X., Emerson, J., Stapp, J., Stapp, L., Abe, P., and Burns, J.L.: Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol 41:4312-4317, 2003.

8. Saiman, L., Marshall, B.C., Mayer-Hamblett, N., Burns, J.L., Quittner, A.L., Cibene, D.A., Coquillette, S., Fieberg, A.Y., Accurso, F.J., and Campbell, P.W., III, for the Macrolide Study Group: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 290:1749-1756, 2003.

9. Ordonez, C.L., Henig, N.R., Mayer-Hamblett, N., Accurso, F.J., Burns, J.L., Chmiel, J.F., Daines, C.L., Gibson, R.L., McNamara, S., Retsch-Bogart, G.Z., Zeitlin, P.L., and Aitken, M.L.: Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Resp Crit Care 168:1471-1475, 2003.

10. Ernst, R.K., D’Argenio, D.A., Ichikawa, J.K., Bangera, M.G., Selgrade, S., Burns, J.L., Hiatt, P., McCoy, K., Brittnacher, M., Kas, A., Spencer, D.H., Olson, M.V., Ramsey, B.W., Lory, S., and Miller, S.I.: Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ Microbiol 5:1341-1349, 2003.

11. Nair, B.M., Cheung, K-J., Griffith, A., and Burns, J.L.: Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J Clin Invest 113:464-473, 2004.

12. Moskowitz, S.M., Foster, J.M., Emerson, J., and Burns, J.L.: Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42:1915-1922, 2004.

13. Urban, T.A., Griffith, A., Torok, A.M., Smolkin, M.E., Burns, J.L., and Goldberg, J.B.: Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation. Infect Immun 72:5126-5134, 2004.

14. Watson, M.E. Jr, Burns, J.L., and Smith, A.L. Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150(Pt 9): 2947-2958, 2004.

15. Beckmann, C., Brittnacher, M., Ernst, R., Mayer-Hamblett, N., Miller, S.I., and Burns, J.L. Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections. Infect Immun 73:444-452, 2005.

16. Nair, B.M., Joachimiak, L.A., Chattopadhyay, S., Montano, I., and Burns, J.L. Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia. FEMS Microbiol Lett 245:337-344, 2005.

17. Moskowitz, S.M., Foster, J.M., Emerson, J.C., Gibson, R.L., and Burns, J.L. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56:879-886, 2005.

18. Smith, E.E., Buckley, D.G., Wu, Z., Saenphimmachak, C., Hoffman, L.R., D'Argenio, D.A., Miller, S.I., Ramsey, B.W., Speert, D.P., Moskowitz, S.M., Burns, J.L., Kaul, R., Olson, M.V. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103:8487-8492, 2006.

19. Gibson, R.L., Retsch-Bogart, G.Z., Oermann, C., Milla, C., Pilewski, J., Daines, C., Ahrens, R., Leon, K., Cohen, M., McNamara, S., Callahan, T.L., Markus, R., and Burns, J.L. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 41:656-665, 2006.

20. Anderson, S.W., Stapp, J.R., Burns, J.L., and Qin, X. Characterization of small colony variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis. J Clin Microbiol 45:529-535, 2007.

21. Mayer-Hamblett, N., Aitken, M.L., Accurso, F.J., Kronmal, R.A., Konstan, M.W., Burns, J.L., Sagel, S.D., and Ramsey, B.W. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 175:822-828, 2007.

22. D’Argenio, D.A., Wu, M., Hoffman, L.R., Kulasekara, H.D., Deziel, E., Smith, E.E., Nguyen, H., Ernst, R.K., Larson Freeman, T.J., Spencer, D.H., Brittnacher, M., Hayden, H.S., Selgrade, S., Klausen, M., Goodlett, D.R., Burns, J.L., Ramsey, B.W., and Miller, S.I. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 64:512-533, 2007.

23. Nguyen, D., Emond, M.J., Mayer-Hamblett, N., Saiman, L., and Burns, J.L. Clinical response to azithromycin in cystic fibrosis correlates with in-vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 42:533-541, 2007.

24. Cheung, K., Li, G., Urban, T.A., Goldberg, J.B., Griffith, A., Lu, F., and Burns, J.L. Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepacia. Microbes Infect 9:829-837, 2007.

25. Gibson, R.L., Emerson, J., Mayer-Hamblett, N., Burns, J.L., McNamara, S., Accurso, F.J., Konstan, M.W., Chatfield, B.A., Retsch-Bogart, G., Waltz, D.A., Acton, J., Zeitlin, P., Hiatt, P., Moss, R., Williams, J., and Ramsey, B.W. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol, 42:610-623, 2007.

© 2007-2018 Seattle Children's Hospital, Research & Foundation

Webmaster (pedweb@uw.edu)